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Abstract For patients with metastatic breast cancer, we
previously described that increased EZH2 expression levels
were associated with an adverse outcome to tamoxifen
therapy. Main objective of the present study is to investi-
gate miR-26a and miR-101 levels, which both target
EZH2, for their association with molecular pathways and
with efficacy of tamoxifen as first-line monotherapy for
metastatic breast cancer. Expression levels were measured
using quantitative Real-Time Polymerase Chain Reaction
(qRT-PCR) in primary breast cancer specimens of 235
estrogen receptor-a (ER)-positive patients. Pathway anal-
ysis was performed on microarray data available for 65
of these tumors. Logistic regression and Cox uni- and
multivariate analysis were performed to relate expression
levels with clinical benefit and time to progression
(TTP). Increasing levels of miR-26a were significantly
(P \ 0.005) associated with both clinical benefit and pro-
longed TTP, whereas miR-101 was not. Cell cycle regu-
lation and CCNE1 and CDC2 were the only significant
overlapping pathway and genes differentially expressed
between tumors with high and low levels of miR-26a and
EZH2, respectively. In addition, increasing mRNA levels
of CCNE1 (P \ 0.05) and CDC2 (P \ 0.001) were related
to poor outcome. Multivariate analysis revealed miR-26a
and CDC2 as an optimal set of markers associated with
outcome on tamoxifen therapy, independently of traditional
predictive factors. To summarize, only miR-26a levels are
related with treatment outcome. Cell cycle regulation is the
only overlapping pathway linked to miR-26a and EZH2
levels. Low mRNA levels of EZH2, CCNE1, and CDC2,
and high levels of miR-26a are associated with favorable
outcome on tamoxifen.
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Introduction
The anti-estrogen tamoxifen has been used for more than
three decades for the treatment of estrogen receptor-a
(ER)-positive breast cancer in both adjuvant and metastatic
settings. The majority of breast tumors express ER, how-
ever, half of the patients with metastatic disease initially
fail to respond to endocrine therapy, while the remaining
patients will develop resistance during therapy. More
insight into factors underlying tamoxifen resistance as well
biomarkers to identify patients likely to benefit from
tamoxifen is therefore needed.
We identified and validated an 81-gene signature that
predicts tamoxifen resistance in patients with metastatic
breast cancer [1, 2]. This signature included a member of
the Enhancer of Zeste Homolog (EZH) family, which
consists of EZH1 (OMIM 601674) and EZH2 (OMIM
601573). EZH2 is one of the polycomb proteins, a highly
conserved group of chromatin modifiers known for their
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role in epigenetic memory and preservation of cellular
characteristics [3]. Our in vitro studies showed that
knockdown of EZH2 upregulates ER as a consequence of
which sensitivity to anti-estrogen therapy increases [4]. In
line with this, we have validated the predictive value of
EZH2 and showed that low EZH2 levels were associated
with favorable outcome on tamoxifen treatment in breast
cancer patients with metastatic disease [4].
MicroRNAs (miRs) consist of a family of endogenously
expressed small noncoding RNAs that target coding
mRNAs to repress translation or induce degradation of
their target mRNAs [5]. There is accumulating evidence
that misregulation of miRs plays an important role in
cancer. In breast cancer, miRs have been related with
metastatic behavior, clinical outcome and ER status [6, 7].
Expression of several miRs in ER-positive breast cancer
have also been associated with response to tamoxifen in
cell lines (miR-221 and -222) [8], and in patients with
metastatic disease treated with first-line tamoxifen (miR-
30a, -30c, and -182) [9].
With respect to EZH2, miR target prediction tools have
indicated that several miRs can target EZH2, but only two
miRs, i.e., miR-26a and miR-101, have actually been
shown to regulate EZH2 expression in different tissues [10,
11]. In the present study, we examined whether miR-26a
and miR-101 were associated with EZH2 mRNA levels in
breast cancer and with outcome on first-line tamoxifen
therapy. In addition, using available whole genome mRNA
data from a subset of tumors, the global testing approach
(GTA) was performed to identify molecular pathways
correlated with expression levels of miR-26a, miR-101,
and EZH2 and to reveal genes, within these pathways, that
associate with outcome on tamoxifen.
Patients and methods
Patients
Frozen breast tumor tissue specimens from female patients
with primary operable breast cancer, who entered the clinic
between 1981 and 1996 were analyzed. Follow-up, tumor
staging, and response to therapy were performed as defined
by standard International Union Against Cancer (Geneva,
Switzerland) classification criteria [12]. This retrospective
study was performed in accordance with the Code of
Conduct of the Federation of Medical Scientific Societies
in the Netherlands (http://www.fmwv.nl), and reported
following the REMARK recommendations [13], wherever
possible. The study has been approved by the medical
ethics committee of the Erasmus MC Rotterdam, The
Netherlands (MEC 02.953).
Tumor protein expression levels of ER and progesterone
receptor (PgR) were determined and used to classify
tumors as ER- and/or PgR-positive as described previously
[4, 14]. The following criteria were applied to include
breast tumor specimens for final analysis in this study: (1)
sufficient frozen tumor material, (2) more than 30% epi-
thelial tumor cell nuclei in haematoxylin/eosin-stained
sections, and (3) specimen of good RNA quality according
to predefined criteria [15]. After applying these criteria,
235 patients with ER-positive tumors, who had metastatic
disease treated with tamoxifen as first-line therapy, were
included in this study. From these 235 patients, 89 patients
(38%) underwent breast-conserving lumpectomy and 146
patients modified mastectomy (62%). The median follow-
up time of patients alive was 89 months, range
10–165 months. Hundred and sixty five patients (70%) did
not receive prior adjuvant systemic therapy, while 42
patients (18%) were previously treated with adjuvant che-
motherapy [25 patients (11%) with non-anthracycline-
based (CMF) and 17 patients (7%) with anthracycline-
based (FAC/FEC) regimens].
Twenty eight patients (12%) presented with distant
metastases at initial diagnosis (M1 patients). Clinical
benefit on first-line tamoxifen monotherapy, defined as a
complete or partial response according to standard Inter-
national Union Against Cancer (Geneva, Switzerland)
classification criteria [12] or no change longer than
6 months after treatment initiation (stable disease), was
observed in 148 patients (63%). Eleven patients (5%)
showed a complete response, 33 (14%) a partial response,
and 104 patients (44%) had stable disease. No clinical
benefit occurred in 87 patients (37%). Time to progression
(TTP) was defined as the time elapsed between initiation of
tamoxifen therapy and first detection of disease
progression.
Methods
Details of applied methodologies are available at Supple-
mental Methods. In brief, tissue processing, RNA isolation,
cDNA synthesis, quantitative Real-Time Polymerase Chain
Reaction (qRT-PCR), and expression data generation were
performed as described previously [15]. For pathway
analysis, samples with whole genome mRNA expression
profiles available, measured on Affymetrix HG-U133A and
Plus2 chips, were selected (N = 65, 28%) and only reli-
able, i.e., quality checked, probes (N = 10,520) were
evaluated. Samples were grouped according to median
expression levels of miR-26a, miR-101 or EZH2. The
Global Test Approach (GTA) was used to identify KEGG/
BioCarta biological pathways in genes co-expressed with
the biomarker of interest [41]. Pathways were taken into
account when P-values, after correction for multiple testing
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and resampling, were below 0.05 and genes with z-scores
[1.96 were considered significant contributors to the
pathways. The GTA package version 4.14.0 was run in the
R version 2.9.0. Data analysis and statistics were per-
formed as previously described [4]. Expression levels of
miR-26a, miR-101, and EZH2, CCNE1, CDC2, ER, and
PgR mRNA levels were transformed to reduce distribution
skewness. Logistic regression analysis was used to com-
pute the odds ratio (OR) for clinical benefit and the Cox
proportional hazards model to calculate the hazard ratio
(HR) for TTP. Computations were done with the STATA
statistical package, release 11.1 (STATA Corp., College
Station, TX). All P-values were two-sided, and P \ 0.05
was considered as statistically significant.
Results
Associations with clinicopathological factors
In this study, we determined the miR-26a, miR-101, and
EZH2 mRNA expression levels in 235 primary breast
carcinomas. The median and interquartile ranges of
expression levels for miR-26a were 0.99 and 0.41, for miR-
101 were 1.03 and 0.81 and for EZH2 were 0.10 and 0.07.
The miR-26a and miR-101 levels correlated with each
other (rs = 0.43, P \ 0.001) and showed an inverse rela-
tion with EZH2 mRNA levels (rs = -0.21 and rs = -
0.15, respectively, P \ 0.05). Expression levels of both
miRs were not significantly related with age, tumor grade,
tumor size, or nodal status (Table 1). Only miR-101 levels
were associated with postmenopausal status (P = 0.036).
The ER and PgR mRNA levels showed a significant
positive correlation with those of miR-26a (rs = 0.21 and
rs = 0.34, for both P \ 0.002) and miR-101 (rs = 0.13,
P = 0.04 and rs = 0.27, P \ 0.001).
Associations with clinical benefit and time
to progression
Expression levels of miR-26a, miR-101 and EZH2 mRNA
levels were evaluated in uni- and multivariate analysis for
their associations with clinical benefit (Supplemental
Table 2) and TTP (Table 2) in patients with metastatic
breast cancer treated with tamoxifen as first-line mono-
therapy. The miR-101 levels were not related with clinical
benefit (OR = 0.84, P = 0.40) nor with TTP (Table 2). As
continuous variable, increasing levels of miR-26a were
significantly associated with clinical benefit (OR = 32.1,
P \ 0.001) and with favorable TTP (HR = 0.13,
P \ 0.001; Table 2). Increasing mRNA levels of EZH2
were related to lower chance of clinical benefit
(OR = 0.61, P = 0.02) and shorter TTP (HR = 1.26,
P = 0.02). Analysis of miR-26a and EZH2 categorized in
thirds (i.e. three quantiles) showed that the third with
highest levels of miR-26a was related to clinical benefit
(OR = 4.10, P \ 0.001) and with prolonged TTP
(HR = 0.43, P \ 0.001), whereas the third with the high-
est EZH2 levels correlated with treatment failure
(OR = 0.34, P = 0.002) and shorter TTP (HR = 1.91,
P \ 0.001). Kaplan–Meier curves as function of catego-
rized expression levels of miR-26a and EZH2 visualize
their association with TTP (Fig. 1). The median differences
in TTP were 6.5 months between patients with high and
low expression levels for miR-26a and 5.6 months for
those with high and low EZH2 expression levels. In mul-
tivariate analysis, when added separately to the base model
of predictive factors, miR-26a and EZH2 were significantly
associated with clinical benefit and TTP, both as continu-
ous and as categorized variables. Patients with high miR-
26a levels showed clinical benefit (OR = 3.31, P = 0.005)
and the longest TTP (HR = 0.52, P \ 0.001), whereas
those with high EZH2 levels had less benefit (OR = 0.39,
P = 0.02) and shorter TTP (HR = 1.80; P = 0.001). The
results of the multivariate analysis show the independence
of miR-26a and EZH2 from traditional predictive factors
included in the base model.
Pathway analysis for miR-26a and EZH2
In an exploratory pathway analysis with GTA, we evalu-
ated 109 KEGG/BioCarta biological pathways and 10,520
mRNAs for differentially expressed pathways and genes.
GTA identified only two pathways which significantly
correlated with miR-26a, and 10 pathways with EZH2
mRNA expression (Table 3). The cyclins and cell cycle
regulation pathway, and genes CCNE1 and CDC2 were the
only overlapping pathway and genes between miR-26a and
EZH2 that contributed significantly (Fig. 2). Increased
expressions of CCNE1 and CDC2 were observed in sam-
ples with low miR-26a levels and in samples with high
EZH2 levels.
To confirm this exploratory analysis, the predictive
value of CCNE1 and CDC2 was evaluated by qRT-PCR.
The median and interquartile mRNA levels were 0.03 and
0.03 for CCNE1 (N = 226), and 9.94 and 7.11 for CDC2
(N = 230), respectively. The mRNA levels of CCNE1 and
CDC2 correlated with each other (rs = 0.44, P \ 0.001)
and showed a positive association with EZH2 mRNA
levels (rs = 0.45 and rs = 0.57, for both P \ 0.001) and an
inverse relation with miR-26a (rs = -0.44 and rs =
-0.30, respectively, for both P B 0.001). The ER and PgR
mRNA expression levels showed an inverse correlation
with those of CCNE1 (rs = -0.14, P = 0.03 and rs =
-0.24, P \ 0.001) and CDC2 (rs = -0.07, P = 0.32 and
rs = -0.27, (P \ 0.001). Expression levels of CDC2 and
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CCNE1 were not related with age, menopausal status,
tumor grade, tumor size, or nodal status (Table 1). In
univariate analysis, increasing mRNA levels of CCNE1
were related to treatment failure (OR = 0.67, P = 0.005;
Supplemental Table 2) and shorter TTP (HR = 1.27,
P \ 0.001; Table 2). In addition, increased expression of
CDC2 was associated with poor clinical benefit (OR =
0.45, P \ 0.001) and TTP (HR = 1.53, P \ 0.001). In
multivariate analysis, CCNE1 and CDC2, when added
separately to the base model, were both independent from
traditional predictive factors for their association with
clinical benefit and TTP (Supplemental Table 2; Table 2).
Categorized into thirds, Kaplan–Meier survival analysis
showed that patients with higher mRNA levels of CCNE1
and CDC2 had a shorter TTP (Fig. 1). Compared to the
group with low tumor levels of CCNE1, those with high
levels of CNNE1 had an OR of 0.33 (P = 0.002) and a HR
of 1.87 (P \ 0.001), respectively. Patients with high tumor
levels of CDC2 had an OR of 0.28 (P \ 0.001) and even a
HR of 2.07 (P \ 0.001), respectively, compared with those
with low tumor CDC2 levels. These results indicate that an
activated cell cycle regulation pathway through increased
expressions of CCNE1 and CDC2 is significantly associ-
ated with poor outcome on tamoxifen therapy. Moreover,
two additional cyclins and cell cycle regulation pathway
genes (E2F1 and CCNB1) were evaluated, next to CCNE2
(not in GTA because it failed quality control), to confirm
the involvement of the cell cycle regulation pathway in the
response to tamoxifen. All three genes showed a significant
association with TTP in uni- and multivariate analyses as
continuous variables, i.e., E2F1 had a HR of 1.38
(P = 0.013), CCNE2 had a HR of 1.38 (P \ 0.001) and
CCNB1 had a HR of 1.86 (P \ 0.001) (Supplemental
Table 3).
Multivariate analysis of miR-26a, EZH2, CCNE1,
and CDC2
To determine a set of predictive biomarkers, the expression
of miR-26a levels and of EZH2, CCNE1, and CDC2
mRNA levels were added simultaneously in a multivariate
analysis to evaluate their relationship with TTP. Both
CCNE1 and EZH2 mRNA levels lost their predictive value
when included with miR-26a and CDC2, defining miR-26a
and CDC2 levels as the set of predictive biomarkers
associated with TTP. The HRs in the simultaneous analysis
of miR-26a and CDC2 as continuous variables were 0.22
(P \ 0.001) and 1.38 (P = 0.001), respectively (Table 2).
Their contribution to the multivariate base model was
independent from traditional predictive factors included in
the model (Table 2). Converting miR-26a and CDC2 levels
into a score followed by categorization into thirds resulted
in a HR of 1.90 for the group with intermediate scores andT
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Table 2 Cox uni- and multivariate analyses for TTP in patients with metastatic disease treated with tamoxifen
Factor of base model N % Univariate analysis Multivariate analysis*
HR 95% CI P HR 95% CI P
Age (year)
B55 87 37 1.00 1.00
55–70 89 38 0.82 0.60–1.11 0.19 0.71 0.45–1.11 0.13
[70 59 25 0.66 0.47–0.94 0.02 0.58 0.36–0.94 0.03
Menopausal status
Premenopausal 56 24 1.00
Postmenopausal 179 76 0.86 0.63–1.17 0.33
Disease-free survival
B1 year 62 26 1.00 1.00
1–3 years 109 46 0.66 0.48–0.91 0.01 0.63 0.46–0.88 0.006
[3 years 64 27 0.51 0.35–0.75 \0.001 0.52 0.36–0.77 0.001
Dominant site of relapse
Soft tissue 26 11 1.00 1.00
Bone 127 54 1.29 0.83–2.02 0.26 1.28 0.79–2.07 0.31
Viscera 82 35 1.12 0.70–1.79 0.64 1.29 0.77–2.15 0.33
ER mRNA 235 100 0.89 0.83–0.94 \0.001 0.90 0.84–0.96 0.002
PgR mRNA 235 100 0.90 0.84–0.96 0.002 0.91 0.85–0.98 0.02
Factors analyzed Additions to base model
mi-26a
Continuous variable 235 100 0.13 0.06–0.28 \0.001 0.18 0.07–0.44 \0.001
Low 79 34 1.00 1.00
Intermediate 78 33 0.93 0.68–1.29 0.68 1.18 0.83–1.66 0.35
High 78 33 0.43 0.31–0.61 \0.001 0.52 0.36–0.76 \0.001
miR-101
Continuous variable 235 100 0.87 0.70–1.07 0.19 0.90 0.71–1.13 0.37
EZH2 mRNA
Continuous variable 235 100 1.26 1.06–1.51 0.01 1.28 1.05–1.56 0.02
Low 79 34 1.00 1.00
Intermediate 78 33 1.58 1.14–2.19 0.006 1.73 1.23–2.44 0.002
High 78 33 1.91 1.37–2.68 \0.001 1.80 1.26–2.55 0.001
CCNE1 mRNA
Continuous variable 226 96 1.27 1.12–1.45 \0.001 1.24 1.06–.144 0.007
Low 76 34 1.00 1.00
Intermediate 75 33 1.19 0.85–1.66 0.31 1.24 0.88–1.76 0.22
High 75 33 1.87 1.33–2.62 \0.001 1.62 1.11–2.35 0.01
CDC2 mRNA
Continuous variable 230 98 1.53 1.29–1.81 \0.001 1.54 1.27–1.87 \0.001
Low 77 34 1.00 1.00
Intermediate 77 33 1.53 1.09–2.13 0.01 1.52 1.07–2.15 0.02
High 76 33 2.07 1.47–2.90 \0.001 2.05 1.42–2.98 \0.001
miR-26a & CDC2
miR-26a 230 98 0.22 0.09–0.52 \0.001 0.27 0.11–0.65 0.004
CDC2 230 98 1.38 1.15–1.65 0.001 1.47 1.20–1.79 \0.001
The expression levels of miR-26a, miR-101 and EZH2, CCNE1, and CDC2 were evaluated both as continuous, and when significant, as categorized
variables in estrogen receptor-positive tumors from 235 patients recurrence of which was treated with first-line tamoxifen monotherapy. Factors were
added separately to the base model in the multivariate analysis, which was stratified for menopausal status as described in our previous study [4]
* The multivariate analysis is stratified for menopausal status
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a HR of 3.03 for the group with highest scores (see Sup-
plemental Figure 1 for Kaplan–Meier survival curves).
Discussion
This study shows that miR-26a levels associate with out-
come of metastatic disease on first-line tamoxifen mono-
therapy, whereas miR-101 does not. Patients with clinical
benefit have high miR-26a and low EZH2 mRNA levels.
Additionally, only the cell cycle regulation pathway with
its genes CCNE1 and CDC2 overlap between miR-26a and
EZH2 linked molecular pathways. These two genes also
correlate with treatment outcome. The miR-26a and CDC2
levels that regulate EZH2 levels and activity were identi-
fied as a set of predictive biomarkers for treatment
outcome.
Overexpression of EZH2 was observed in prostate and
breast cancer in which it was associated with aggressive
clinical behavior [16, 17]. We demonstrated that decreased
EZH2 mRNA levels were predictive for favorable outcome
on tamoxifen in metastatic breast cancer [4]. Both miR-26a
and miR-101 repress EZH2 expression [10, 11, 18].
Although miR-26a and miR-101 expressions correlate with
EZH2 levels in our current study, only miR-26a had a
significant association with outcome on tamoxifen.
Expression of miR-26a is repressed by estrogens in vitro
and is induced in breast cancer patients treated with anti-
estrogen neoadjuvant therapy [19] whereas miR-101
expression is upregulated by androgen stimulation [18], but
is not regulated by estrogens [19, 20]. The fact that
androgens stimulate miR-101 expression, whereas estro-
gens repress miR-26a expression needs to be elucidated,
but suggests that EZH2 repression by miR-26a and miR-
101 might be tissue as well as hormone dependent. That
only miR-26a and not miR-101 has a relation with treat-
ment outcome is because these miRs target many other
genes. Of the genes predicted to be targets of miR-26a
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Fig. 1 Kaplan–Meier curves of TTP as a function of miR-26a,
EZH2, CCNE1, and CDC2 expression levels. Patients were evenly
divided into three groups according to their expression levels. Curves
were generated as function of low, intermediate, and high miR-26a,
EZH2, CCNE1, and CDC2 expression levels. Patients at risk at
different time points are indicated
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Table 3 miR-26a and EZH2 related pathways and genes
Global testing approach—KEGG/BioCarta pathway analysis
Genes
tested
P Genes significant (z-score [1.96)
miR-26a associated pathways
Cyclins and cell cycle regulation 18 0.008 CCNE1,CDK7,CDKN2D,CDC2
TPO signaling pathway 18 0.018 HRAS,THPO,RASA1
EZH2 associated pathways
Cell cycle G1 S check point 21 0.002 TGFB1,E2F1,ATM,SMAD4,CDC2,CCNE1,SKP2,ATR,ABL1
Role of BRCA1 BRCA2 and ATR in
cancer susceptibility
20 0.003 FANCG,RAD51,ATM,FANCA,CHEK1,ATR,RAD9A,NBN,FANCC,BRCA1
Cyclins and cell cycle regulation 18 0.005 CCNB1,E2F1,CDC2,CCNE1,CCND2
ATM signaling pathway 16 0.011 RAD51,ATM,NFKB1,CHEK1,GADD45A,ABL1,NBN,BRCA1
Spliceosomal assembly 15 0.018 SNRPD1,SNRPG,SNRPF,U2AF1,SFRS2,U2AF2,SNRPE,SNRPA1
Cytokines and inflammatory response 15 0.019 TGFB1,HLA-DRA,IL15,CD4,CSF1,LTA
Cell cycle G2 M checkpoint 21 0.025 CCNB1,ATM,CDC2,PLK1,CHEK1,ATR,WEE1,GADD45A,BRCA1
ADPRibosylation factor 15 0.029 KDELR1,ARFGAP1,DDEF2,PSCD4,COPA,CENTD1
Hypoxia and p53 in the cardiovascular
system
16 0.038 ATM,FHL2,CSNK1A1,GADD45A
p38 MAPK signaling pathway 32 0.044 TGFB1,CREB1,DAXX,CDC42,DDIT3,MAPKAPK5,HMGN1,HRAS,PLA2G4A
In 65 breast cancer samples, for which whole-genome mRNA expression profiles were available, pathways and genes were identified with the
GTA of 109 KEGG/BioCarta biological pathways and 10,520 mRNAs. Only those pathways and their genes are indicated, which show a
significant relationship with miR-26a and EZH2 expression levels. The number of genes tested is indicated per pathway. The P-values determine
the significance of the association after correction for multiple testing and resampling
TFDP1
CCNB1
CDC2
CDKN1A
RB1
CCND1
E2F1
CDK4
CDK7
CDKN1B
CCNE1
CCNH
CCND2
CCNA1
CDKN2D
CDKN2A
CDKN2C
CCND3
Fig. 2 Global testing approach
result of the cyclins and cell
cycle regulation pathway. This
pathway was overlapping
between miR-26a- and EZH2-
related pathways. Red bars
illustrate high expression levels
of the pathway gene in samples
with high miR-26a or EZH2
levels, whereas green bars
indicate high expression levels
in samples with low miR-26a or
EZH2 levels. The number of
vertical markers in a bar
indicates the significance and
the height of a bar the
contribution of a gene to the
pathway. The continuous line
shows the threshold for
significance; bars with more
than two lines above this border
are significantly (P \ 0.05)
differentially expressed genes
within the pathway, which are
also indicated with an asterisk.
Only CCNE1 and CDC2
showed significant associations
with both miR-26a and EZH2
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(1,012 targets) and miR-101 (1,198 targets), only a few (66
genes, including EZH2) are targeted by both miRs (data
not shown). We cannot exclude another relevant gene for
endocrine therapy outcome as specific miR-26a target
which is not targeted by miR-101. This certainly needs
further exploration but is not within the scope of the current
study.
Our pathway analyses identified only the cell cycle
regulation pathway to be correlated with miR-26a and
EZH2 levels. The genes CDK7, CCNE1, CDC2, and
CDKN2D for miR-26a and CCNB1, CCNE1, CDC2,
CCND2, and E2F1 for EZH2 were differentially expressed
within this pathway. CCNE2 and CDK2, important genes
in this pathway, were not included in the analyses because
their probes failed quality control. The association of EZH2
with cell cycle regulation is extensively reported [21, 22].
Moreover, the Targetscan algorithm predicted cyclins D2,
E1, and E2 (CCND2, CCNE1, and CCNE2), and cyclin
dependent kinase 6 (CDK6), which all play a role in the
G1–S transition, as miR-26a targets [23]. Finally, estrogens
that regulate G1 cyclin-dependent kinases [24] and
tamoxifen has a cytostatic effect on breast cancer cells and
arrest them in G0/G1 phase [25].
Based on our study, CCNE1 and CDC2 were the only
overlapping genes for miR-26a and EZH2. We have shown
earlier Cyclin E as prognostic marker for lymph node-
negative breast cancer [26]. Now, we show that in the
metastatic disease setting, high CCNE1 mRNA levels
correlate with poor outcome on tamoxifen. In concordance,
patients with high CCNE protein levels had less benefit
from tamoxifen in an adjuvant setting [27], and the over-
expression of low molecular weight CCNE isoforms was
associated with resistance to fulvestrant [28] and letrozole
[29]. CCNE1 is a kinase and regulatory subunit of CDK2
that accumulates at the G1–S phase [30].
The second gene, CDC2 [also known as cyclin-depen-
dent kinase 1 (CDK1)], correlated with miR-26a and EZH2
and treatment outcome. CDC2 is a mitotic cyclin-depen-
dent Ser/Thr protein kinase and the master controller of
mammalian cell–cycle regulation which is activated by
CDK7 phosphorylation [31, 32]. At present, expression of
CDC2 has been linked to response to tamoxifen in cell line
models [33], and we now show an 8-month delay in disease
progression in patients with the lowest CDC2 mRNA levels
compared with those with the highest expression levels.
Thus, the status of the cell cycle regulation pathway,
specified by CCNE1 and CDC2 levels but also confirmed
by CCNB1, CCNE2, and E2F1, seems to play a role in how
the metastasis will respond to first-line tamoxifen therapy.
Multivariate analysis of miR-26a, EZH2, CCNE1, and
CDC2 to determine their associations with treatment out-
come showed that the predictive values of EZH2 and
CCNE1 levels were less significant than those of miR-26a
and CDC2. Interestingly, not only miR-26a but also CDC2
Fig. 3 The regulatory network of EZH2. A model for the modulation
of the expression and activity of EZH2 based on our results and
available data in the literature. Binding of miR-101 and miR-26a to
the 30-UTR blocks transcription of EZH2 [10, 11]. Our data linked
expression levels of miR-26a and EZH2 by the GTA of pathways to
the cyclins and cell cycle regulation pathway with two significant
genes [CCNE1 and CDC2 (CDK1)]. CDC2 (CDK1) and CDK2
activate EZH2 through the phosphorylation of its Thr350 residue [34–
36]. Our study shows that, in breast cancer, miR-26a and CDC2 might
be involved in the regulation EZH2 expression and activity,
respectively, and as a result associate with response to tamoxifen
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have a physical interaction with EZH2 (Fig. 3), although
with opposite effects on EZH2 functioning. As mentioned,
miR-26a binds to the 30-UTR of EZH2 and inhibits tran-
scription of EZH2. On the other hand, CDC2 (CDK1) and
CDK2 have been shown to activate EZH2 by phosphory-
lation of its Thr350 residue [34–36]. This Thr350 phos-
phorylation is necessary for EZH2 recruitment at target loci
and for maintenance of H2K27me3 levels [34]. Since
EZH2 expression and activity are higher in proliferating
rather than differentiating cells [22], both miR-26a and
CDC2 may define endocrine-responsive or -resistant phe-
notypes of ER-positive breast cancer cells through their
modulation of EZH2 levels and activity. In ER-negative
breast cancer cells, EZH2 knockdown results in increased
CDC2 and pCDC2 protein expressions [37], but recently it
was suggested that EZH2 in ER-negative tumors functions
as a transcriptional activator but acts as a repressor in ER-
positive tumors [38].
Therapeutics that can modulate miR-26a, CDC2, or
EZH2 activity might be an attractive strategy for patients
resistant to tamoxifen to resensitize them for anti-estrogen
treatment. Systemic administration of miR-26a with adeno-
associated virus in mouse models results in decreased
cancer cell proliferation and suppressed tumor progression
[23]. Preclinical evaluation of CDC2 and CDK2 inhibitors
revealed G2/M arrest and cell death in both anti-estrogen-
sensitive and resistant cells [33]. Hydrolase inhibitors, such
as DZNep, induce EZH2 depletion in breast cancer cell
lines and result in cell cycle arrest and apoptosis [39, 40].
At the end, all these treatments target EZH2 levels and
activity. We hypothesize that patients resistant to tamoxi-
fen with low miR-26a and high CDC2 and EZH2 levels in
their primary tumor may benefit from these treatment
strategies in order to overcome tamoxifen resistance.
In summary, we have shown that high miR-26a and low
EZH2 mRNA levels associate with clinical benefit and
prolonged TTP. The cell cycle regulation pathway and its
genes CCNE1 and CDC2 correlate significantly with miR-
26a and EZH2 levels and with outcome on tamoxifen.
Multivariate analysis revealed miR-26a and CDC2 as sets
of biomarkers to predict outcome on tamoxifen in meta-
static breast cancer. Our findings might help one to
improve the identification of individual patients resistant to
tamoxifen, who may benefit from therapeutics that block
EZH2 expression and activity.
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